Dendreon's IMPACT trial met "unambiguous" statistical significance.
That's enough for me... lots of details out there remain to be shown at the AUA meeting on 4/28, but they passed. They will resubmit the BLA in the fourth quarter - no other real news.
Congratulations to Dendreon, and to cancer patients. Bring on the pipeline!
Regards,
Trond
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment